Drugs that contain Apixaban
1. List of Eliquis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6967208 | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
Nov, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9326945 | BRISTOL MYERS SQUIBB | Apixaban formulations |
Feb, 2031
(8 years from now) | |
Market Authorisation Date: 28 December, 2012
Treatment: Prophylaxis of deep vein thrombosis and pulmonary embolism; Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Reduce the risk of recurrent deep vein thrombosis (dvt); Treatment of deep vein thrombosis (dvt); Reduce the risk of recurrent pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Reducing the risk of stroke; Prophylaxis of pulmonary embolism
Dosage: TABLET;ORAL
How can I launch a generic of ELIQUIS before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic